Effect of vitamin D(3) supplementation on cardiometabolic disease risk among overweight/obese adult males in the UK: A pilot randomised controlled trial

BACKGROUND: Observational studies suggest links between reduced serum 25(OH)D concentration and increased cardiometabolic disease risk. However, these studies provide limited evidence of causation, with few conclusive randomised controlled trials (RCT) having been carried out to date. This RCT investigated the effect of vitamin D(3) supplementation on vascular function and cardiometabolic disease risk markers, in 55 healthy males aged 18–65 years with plasma 25(OH)D concentration <75 mol L(–1) and body mass index ≥24.9 kg m(–2). METHODS: Participants were assigned to consume 125 µg day(–1) (5000 IU day(–1)) vitamin D(3) or placebo for 8 weeks. Blood samples and vascular function measures were obtained at baseline, as well as at weeks 4 and 8. The primary outcome was arterial stiffness, an indicator of cardiovascular disease (CVD) risk, assessed by pulse wave velocity. Biomarkers of CVD risk, insulin resistance and endothelial function were measured using an enzyme‐linked immunosorbent assay. RESULTS: Daily oral intake of 125 µg supplemental vitamin D(3) led to a significant improvement in plasma 25(OH)D concentrations over the 8‐week intervention in the vitamin D group compared to the change in the placebo group (p ˂ 0.001). In the vitamin D group, the baseline mean ± SD 25(OH)D concentration was 38.4 ± 15.9 and this increased to 72.8 ± 16.1 nmol L(–1) after 8 weeks of supplementation. The intervention had no effect on arterial stiffness, as measured by pulse wave velocity, although vitamin D(3) supplementation did lead to a decrease in mean ± SD brachial pulse pressure from baseline to 8 weeks of −2.9 ± 3.4 mmHg (p = 0.027) in the vitamin D group compared to the same period in the placebo group. The intervention had no effect on the remaining cardiometabolic parameters. CONCLUSIONS: Overall, treatment significantly improved brachial pulse pressure but no other cardiometabolic disease risk markers. To follow on from this pilot RCT, future large‐scale clinical trials over longer durations may offer further insights.